Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThe Mission Group Regulatory News (TMG)

Share Price Information for The Mission Group (TMG)

Share Price is delayed by 15 minutes
Get Live Data
16.75    0.00 (0.00%)
Bid:
16.50
Ask:
17.00
Spread: 0.50 (3.03%)
Market Cap: £15.18m
TMG Live PriceLast checked at - London Stock Exchange

Intraday The Mission Group Share Chart

Update on Possible Offer for The Mission Group plc

10 Jun 2024 07:00

RNS Number : 7025R
Brave Bison Group PLC
10 June 2024
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

THIS ANNOUNCEMENT IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE " CODE").

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

FOR IMMEDIATE RELEASE.

 

10 June 2024

 

Brave Bison Group plc

 

("Brave Bison", together with its subsidiaries "the Group") 

 

Update on Possible Offer

 

for

 

The Mission Group plc

 

No Intention to Make a Firm Offer

 

On 13 May 2024 Brave Bison announced it was considering an offer to acquire The Mission Group plc (the "Possible Offer" and "Mission"). On 3 June 2024, Brave Bison announced that it had submitted a revised proposal with enhanced terms to Mission (the "Revised Proposal"), which was subsequently rejected by the Mission Board on 6 June 2024.

 

The Revised Proposal provided for an exchange ratio of 13.9 Brave Bison shares for each Mission share. Based on the undisturbed Brave Bison share price of 2.525 pence per share on 10 May, the Revised Proposal represented a value for each Mission share of approximately 35.1 pence, representing a 55 per cent. premium to the undisturbed share price of 22.7 pence on 10 May 2024. The Revised Proposal also included a partial cash alternative of up to 50% of the offer value.

 

As part of the potential transaction, Brave Bison stated its intention to pay down a portion of Mission's £26.8 million of net debt to create a sustainable capital structure for the enlarged company.

 

The Mission Board, led by the Chairman, rejected Brave Bison's attempts for constructive dialogue and chose not to provide access to due diligence information or key management personnel. Further, the Mission Board has not offered an extension to the PUSU deadline by which Brave Bison would be required to make a firm offer for Mission pursuant to Rule 2.7 of the Code.

 

The Board of Brave Bison is disappointed by the lack of engagement from the Mission Board and does not believe that the Mission Board's strategy to deleverage the business will deliver value for Mission shareholders in excess of the Revised Proposal.

 

Brave Bison is a disciplined acquirer and is not willing to advance the Possible Offer without due diligence or access to key management. As such, Brave Bison confirms that it does not intend to make an offer for Mission under Rule 2.7 of the Code. This is a statement to which Rule 2.8 of the Code applies.

 

For the purposes of Note 2 on Rule 2.8 of the Code, Brave Bison, and any person(s) acting in concert with it, reserve the right to make or participate in an offer or possible offer for Mission (and/or take any other action which would otherwise be restricted under Rule 2.8 of the Code) within six months of the date of this announcement in the following circumstances:

 

a) with the agreement of the Mission Board;

 

b) following the announcement of a firm intention to make an offer for Mission by or on behalf of a third party;

 

c) following the announcement by Mission of a Rule 9 waiver proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the Code) or a reverse takeover (as defined in the Code); or

 

d) where the Panel on Takeovers and Mergers has determined that there has been a material change of circumstances.

 

For further information please contact: 

 

Brave Bison Group plc via Hannam & Partners

Oliver Green, Executive Chairman

Theo Green, Chief Growth Officer 

Philippa Norridge, Chief Financial Officer 

 

Hannam & Partners Tel: +44 (0) 20 7907 8500

Financial Adviser

Andrew Chubb

Ernest Bell

Lucia Sviatkova

 

Cavendish Capital Markets Tel: +44 (0) 20 7220 0500

Nominated Adviser & Broker

Ben Jeynes 

Dan Hodkinson 

 

Powerscourt Tel: +44 (0) 20 7250 1446

Financial PR

Elly Williamson

Pete Lambie

Ollie Simmonds

Bravebison@powerscourt-group.com

 

Important information

 

This announcement does not constitute a prospectus or prospectus equivalent document. This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to this announcement or otherwise. Neither Brave Bison nor Mission shareholders should make any investment decision in relation to the Possible Offer except on the basis of certain offer documentation published by Brave Bison and/or Mission in due course. Any offer, if made, will be made solely by certain offer documentation which will contain the full terms and conditions of any offer, including details of how it may be accepted.

 

The distribution of this announcement in jurisdictions other than the United Kingdom and the availability of any offer to shareholders of Brave Bison who are not resident in the United Kingdom may be affected by the laws of relevant jurisdictions. Therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom or shareholders of Brave Bison who are not resident in the United Kingdom will need to inform themselves about, and observe, any applicable requirements.

 

Disclaimer

 

H&P Advisory Ltd ("Hannam & Partners"), which is regulated in the United Kingdom by the Financial Conduct Authority, is acting exclusively for Brave Bison and no-one else in connection with the possible offer and will not be responsible to anyone other than Brave Bison for providing the protections afforded to clients of Hannam & Partners nor for providing advice in relation to the acquisition or any other matters referred to in this announcement.

 

Cavendish Capital Markets Limited ("Cavendish"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively for Brave Bison and no one else and will not be responsible to anyone other than Brave Bison for providing the protections offered to clients of Cavendish or for providing advice in connection with any matter referred to in this Announcement. Neither Cavendish nor any of its affiliates (nor their respective directors, officers, employees or agents) owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cavendish in connection with this Announcement, any statement contained herein, the Acquisition or otherwise. No representation or warranty, express or implied, is made by Cavendish as to the contents of this Announcement.

 

Forward-looking statements

 

This announcement and certain oral statements made regarding the Possible Offer and other information published by Brave Bison containing statements about Brave Bison, Mission and/or the combined group are or may be deemed to be forward-looking statements. All statements other than statements of historical facts included in this announcement, may be forward-looking statements. Without limitation, any statements preceded or followed by or that include the words "targets", "plans", "believes", "expects", "aims", "intends", "hopes", "continues", "would", "could", "should", "will", "may", "anticipates", "estimates", "projects" or words or terms of similar substance or the negative thereof, are forward-looking statements. Forward-looking statements include statements relating to the following: (i) future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; and (ii) business and management strategies and the expansion and growth of Brave Bison, Mission or the combined group's operations and potential cost and operating synergies resulting from the Possible Offer. These forward-looking statements are not based on historical fact and are not guarantees of future performance. By their nature, such forward-looking statements involve known and unknown risks and uncertainties that could significantly affect expected results and are based on certain key assumptions. Many factors could cause actual results to differ materially from those projected or implied in any forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the entities' ability to control or estimate precisely. These factors include, but are not limited to, changes in political and economic conditions, changes in levels of capital investment, success of business and operating initiatives, the impact of any acquisitions or similar transactions, changes in tenants' strategies and stability, changes in the regulatory environment and fluctuations of rates, and changes in tax rates. Except as expressly provided in this announcement, they have not been reviewed by the auditors of Brave Bison or Mission. Neither Brave Bison, nor any of its respective members, associates or directors, officers, employees or advisers, provides any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur. Neither Brave Bison, nor any of its respective members, associates or directors, officers, employees or advisers assumes any obligation to update or correct the information contained in this announcement except as required by applicable law. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this announcement. Brave Bison disclaims any obligation to correct or update any forward-looking or other statements contained in this announcement, except as required by applicable law or by the rules of any competent regulatory authority, whether as a result of new information, future events or otherwise.

 

No profit forecasts or estimates

 

Except as otherwise set out herein, nothing in this announcement (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement in this announcement should be interpreted to mean that earnings or earnings per share or dividend per share for Brave Bison or Mission, as appropriate, for the current or future financial years would necessarily match or exceed the historical published earnings or earnings per share or dividend per share for Brave Bison or Mission, as appropriate.

 

Sources & Bases of Information

 

1. The indicative offer value per share of 35.10 pence has been calculated with reference to the Brave Bison closing price of 2.525p as at 10 May 2024, being the last trading day prior to the possible offer announcements released by Brave Bison and Mission on 12 and 13 May 2024 respectively.

 

2. The premium has been calculated by reference to a price of 22.7 pence per Mission share, being the closing price on 10 May 2024 (being the last trading day prior to the date of the Possible Offer announcement).

 

3. 30 April 2024 Mission net debt calculated as net bank debt of £22.2 million, acquisition obligations of £4.1 million and HMRC Time to Pay agreement of £0.5, as announced by Mission on 13 May 2024.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
OUPEAEKNELXLEFA
Date   Source Headline
15th Jun 20261:00 pmRNSResult of AGM
15th Jun 20267:00 amRNSAGM Trading Update
4th Jun 20267:00 amRNSNotice of AGM and Posting of Annual Report
21st May 202611:46 amRNSDirector/PDMR Shareholding
1st May 20262:45 pmRNSHolding(s) in Company
28th Apr 202611:00 amRNSHolding(s) in Company
27th Mar 20264:50 pmRNSHolding(s) in Company
24th Mar 20267:00 amRNSFinal Results
20th Mar 202612:00 pmRNSNotice of Investor Presentation
18th Feb 20267:00 amRNSGrowth Share Scheme
13th Jan 20267:00 amRNSBoard Changes
13th Jan 20267:00 amRNSFull Year Trading Update
17th Oct 20257:00 amRNSDirectorate Change
10th Oct 20257:00 amRNSDirector/PDMR Shareholding
23rd Sep 20257:00 amRNSINTERIM RESULTS FOR THE SIX MONTHS TO 30 JUNE 2025
12th Sep 20257:00 amRNSBOARD CHANGES
22nd Aug 20257:00 amRNSNOTICE OF RESULTS AND INVESTOR PRESENTATION
12th Aug 20254:22 pmRNSHolding(s) in Company
6th Aug 20256:24 pmRNSHolding(s) in Company
24th Jul 20257:00 amRNSTrading Update
1st Jul 20257:00 amRNSMISSION Group plc appoints John Carey as new CEO
16th Jun 20251:19 pmRNSResult of AGM
16th Jun 20257:00 amRNSAGM Trading Update
11th Jun 202511:44 amRNSNotice of AGM and Posting of Annual Report
28th Mar 20257:00 amRNSTransaction in Own Shares
27th Mar 202510:16 amRNSTransaction in Own Shares
27th Mar 20257:00 amRNSTransaction in Own Shares
25th Mar 20257:00 amRNSFINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
10th Mar 20257:00 amRNSInvestor Presentation
17th Feb 20257:00 amRNSTransaction in Own Shares
11th Feb 20257:00 amRNSTransaction in Own Shares
6th Feb 20257:00 amRNSTransaction in Own Shares
4th Feb 20257:00 amRNSTransaction in Own Shares
30th Jan 20257:00 amRNSTransaction in Own Shares
27th Jan 20257:00 amRNSTransaction in Own Shares
24th Jan 20257:00 amRNSTransaction in Own Shares
23rd Jan 20257:00 amRNSTransaction in Own Shares
22nd Jan 20258:00 amRNSTransaction in Own Shares
21st Jan 20257:00 amRNS2024 Full Year Trading Update
13th Jan 20259:30 amRNSHolding(s) in Company
10th Jan 20257:00 amRNSTransaction in Own Shares
8th Jan 20257:00 amRNSTransaction in Own Shares
6th Jan 20253:47 pmRNSHolding(s) in Company
6th Jan 20257:00 amRNSTransaction in Own Shares
3rd Jan 20257:00 amRNSDirector/PDMR Shareholding
2nd Jan 20257:00 amRNSDirectorate Change
2nd Jan 20257:00 amRNSShare buyback programme
2nd Jan 20257:00 amRNSDisposal and Capital Allocation Update
21st Nov 20247:00 amRNSDirectorate Change
24th Sep 20247:00 amRNSINTERIM RESULTS FOR THE SIX MONTHS TO 30 JUNE 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.